Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy

Inclusion Criteria: * LDL \> 100 * Male or Non-Pregnant Female. Women must be surgically sterile or postmenopausal and not using hormone replacement therapy (HRT) or using a stable, consistent HRT dose with intentions to continue therapy throughout the course of the study * Mentally competent to understand study rationale and protocol * Speak and read English * Currently receiving low to moderate dose statin therapy with plans to continue to the same dose for at least 8 weeks. Low to moderate dose statins include the following daily doses: atorvastatin ≤20 mg, fluvastatin ≤40 mg, lovastatin ≤40 mg, pravastatin ≤40 mg, rosuvastatin ≤10 mg, simvastatin ≤ 40 mg Exclusion Criteria: * LDL \< 100 * Sensitivity to policosanol * Currently taking a high-dose statin or other lipid-lowering agents (i.e. high-dose niacin formulations \[\>500mg/day\], bile-acid sequestrants, ezetimibe, fibrates and high-dose Omega-3 fish oils \[\>900mg of combined EPA/DHA daily\]) * Currently taking medications which have the potential to interact with policosanol (i.e. warfarin, high-dose aspirin) * Active liver disease or ALT level 2.5 times the upper limit of normal * Chronic disease involving hepatic, renal or coronary artery disease * Currently experiencing "flu-like" symptoms * Currently experiencing any form of acute physical injury * Acute psychiatric disorders * Immuno-compromised state * Currently taking systemic steroidal drugs * Currently pregnant or lactating * Females of childbearing potential * Dependence on alcohol or illicit drugs * Participation in any other clinical trial within the last 30 days * Displays s/s of acute systemic infection (oral temperature \>100°F, WBC\>12x10³/µL)